147 results about "Tuberculosis vaccines" patented technology

The invention relates to a mycobacterium tuberculosis LAM oligosaccharide conjugate as well as a preparation method and application thereof. A structural general formula of the mycobacterium tuberculosis LAM oligosaccharide conjugate is described in the specification. The invention also relates to application of the mycobacterium tuberculosis LAM oligosaccharide conjugate in preparation of a tuberculosis vaccine. In the mycobacterium tuberculosis LAM oligosaccharide conjugate, a chemical structure of oligosaccharide is definite and single, is not a mixture and can be synthesized by adopting a chemical method, the problem that immune protection force of a Bacilli Calmette Guerin vaccine is small can be solved, better immune effect can be produced to the crowd with low immunity, and the problem that bacterial drug resistance is produced as antibiotics are greatly used, can be solved.

The invention relates to a selection method for epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the function thereof, in particular to the molecule mimic peptide of the epitope with vaccine development prospect from the mycobacterium tuberculosis and the coding DNA thereof. The selection method of epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the function thereof provides T lymphocyte epitope contained in one important gene Ag85B in the research of mycobacterium tuberculosis and the method of deducting or selecting the epitope, which is beneficial to further developing novel multivalent and poly epitope tuberculosis vaccine and prevent and control the happening and development of tuberculosis; the method makes a foundation of the future development of synthesizing peptide vaccine epitope vaccine and dna vaccine by using epitope and provides molecule mimic peptide of epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the peptide has the amino acid sequence of FVRSSNLKFQDAYNA(SEQ ID NO:1).

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention relates to a recombinant virus carrier which can co-express tubercle bacillus Ag85a, ESAT6 and/or Ag85a/ESAT6 fusion protein as well as any immune auxiliary factor; an expression cassette containing at least one type of tubercle bacillus Ag85a coding sequence, ESAT6 coding sequence and Ag85a/ESAT6 fusion protein coding sequence and the any immune auxiliary factor coding sequence is inserted into a gene group DNA of the recombinant virus carrier. The invention also relates to a host cell containing the virus carrier, a pharmaceutical composition and a preparation method thereof. The recombinant virus carrier can co-express a plurality of antigens of m.tuberculosis and/or cell factors, and has improved prevention and/or curing effect to tuberculosis.

The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

The invention relates to a recombinant bacillus Calmette-Guerin vaccine and its preparation method, wherein tuberculosis mycobacterium ag85b, esat-6 and IFN-gamma gene sequences are inserted into colibacillus-tuberculosis mycobacterium shuttle plasmids to form recombinant plasmid, and are transformed into BCG to form recombinant tuberculosis vaccine. The recombinant vaccine can be used for prevention and treatment of tuberculosis with better immunological effects than BCG.

A live recombinant Mycobacterium bovis-BCG strain comprising a nucleic acid encoding PhoP protein and/or one or more phoP regulon proteins is provided, in which the nucleic acid is capable of being overexpressed. A vaccine or immunogenic composition comprising the live recombinant Mycobacterium bovis-BCG strain and a method for treatment or prophylaxis of a mammal against challenge by Mycobacterium tuberculosis or Mycobacterium bovis are also provided.

The invention relates to the construction of a human GM-CSF gene and Mycobacterium tuberculosis ESAT6 gene chimerically expressed GMCSF-ESAT6 protein recombinant Bacillus Calmette Guerin (BCG) vaccine and immunogenicity research thereof, namely the sequence of the human GM-CFS gene and the sequence of the Mycobacterium tuberculosis ESAT6 gene are inserted into the sequence of the same escherichiacoli-Mycobacterium tuberculosis shuttle plasmid pMV361 by gene engineering technology so as to construct a recombinant shuttle plasmid rpMV361GMCSF-ESAT6; and a vector is introduced into a BCG vaccine by an electroporation method so as to construct a recombinant BCG vaccine rBCG:GMCSF-ESAT6. The recombinant BCG vaccine can express the human GM-CSF and Mycobacterium tuberculosis ESAT6 gene chimeric protein GMCSF-ESAT6 stably, and has an immunogenicity superior to that of the conventional BCG vaccine. The invention provides a process for preparing the recombinant BCG vaccine, researches the immunity thereof, and belongs to the field of gene engineering and the field of tuberculosis vaccine. The novel recombinant vaccine prevents the generation and the propagration of tuberculosis more effectively.

The present invention relates to applications of Mycobacterium tuberculosis antigen protein Rv0446c and a T-cell epitope peptide thereof in preparation of tuberculosis detection reagents, vaccines and medicines, wherein the amino acid sequences of the antigen protein Rv0446c and the T-cell epitope peptide thereof are respectively represented by SEQ ID NO:1-5. According to the present invention, the Mycobacterium tuberculosis antigen protein Rv0446c and the T-cell epitope peptide thereof are used as the stimulants for the specific T cell and B cell immune response caused by Mycobacterium tuberculosis infection, and the false positive caused by the impure antigen can be reduced compared with the use of the complete antigen in the prior art; and the detection reagents prepared from the antigen protein Rv0446c and the T-cell epitope peptide thereof can be widely used for assisted diagnosis of tuberculosis, epidemiological surveillance and other related fields, and the tuberculosis vaccines and the anti-tuberculosis drugs prepared from the antigen protein Rv0446c and the T-cell epitope peptide thereof can be used for prevention and treatment of tuberculosis.

Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.

The invention discloses an antituberculous CTL (Cytotoxic T Lymphocyte) epitope peptide with a drug-resistant related efflux protein source for tuberculosis. The antituberculous CTL epitope peptide is nonapeptide, wherein the amino acid sequence of the nonapeptide is P9: ALGML IAGL. Predicative analysis is carried out on HLA-A*0210 restrictive CTL epitope of drug-resistant related protein antigen for tuberculosis by adopting immune-informatics means and SYFPEITH1, BIMAS and NetCTL1.2 databases according to the primary structure of the antigen, so that the epitope peptide is obtained by screening; and the identified nonapeptide has not been reported in any document. An in-virto ELISPOT (Enzyme-Linked Immunospot Assay) is adopted to identify the epitope peptide; and the identification result provides a theoretical basis for developing tuberculosis vaccine based on drug-resistant related protein antigen and provides more information for designing multi-epitope peptide vaccine for tuberculosi based on the mixed T cell epitope.

The invention provides a preparation method of recombinant protein CFP-10 nanoparticles and the application thereof in preparing tuberculosis prevention vaccines. The preparation method includes the steps of (1) configuration of a polylactic acid-glycolic acid copolymer PLGA solution; (2) configuration of a recombinant protein CFP-10 solution; (3) preparation of primary emulsion; (4) preparation of compound emulsion; (5) formation of the nanoparticles. The recombinant protein CFP-10 nanoparticles prepared by the preparation method are used for enhancing the immunity of BCG-immunized mice through intranasal drip, and it is confirmed that the recombinant protein CFP 10 nanoparticles have the effects of improving mucosal immunity level and promoting BCG immunity.

The invention provides a method for establishment of a Mycobacterium tuberculosis naturally infected non-human primate model. According to the invention, a healthy non-human primate and a non-human primate artificially infected with tuberculosis and suffering cough are raised in an air flow self-circulation combined type negative pressure isolator so as to infect the healthy non-human primate with tuberculosis. Establishment of the natural infection model helps to reveal conditional factors (like HIV) activating latent tuberculosis infection and related mechanisms. The non-human primate model with more clinical significance is provided for research, development and evaluation of anti-tuberculosis vaccines and drugs.

This invention is associated with the gene engineering field and tuberculosis vaccines field. In recent decades, the increase of tuberculosis drug resistant strain and the coinfection of mycobacterium tuberculosis and HIV lead the increase of incidence of tuberculosis, and made it the second killer of human after HIV. Recently, the only tuberculosis vaccines used globally is BCG. This invention inserts the most important protective antigen gene of mycobacterium tuberculosis and missed mycobacterium tuberculosis gene in BCG to the multi-cloning coliform - mycobacterium tuberculosis shuttle-plasmid multiple cloning sites to form recombined plasmid and transforms it to the BCG to form recombined tuberculosis vaccines. The result of experiment shows that, compared with BCG vaccine, the protective antigen can express more efficient, the original missing Rv3425 antigen also get expressed, and the induced IFN- gamma expression also increased significently. This indicates that the recombined tuberculosis vaccines can induce higher cell immunity level than BCG.

The invention discloses a mycobacterium tuberculosis EEC fusion protein. The amino acid sequence of the fusion protein is SEQ ID NO.8 in a sequence table; polynucleotide for encoding the polypeptide is shown as SEQ ID NO.7 in the sequence table; and the fusion protein contains a carrier of the polynucleotide and host cells. The invention further relates to preparation of the fusion protein, and effects of the fusion protein in tuberculosis auxiliary diagnosis, tubercle bacillus infection screening and tuberculosis vaccine development.